Gentis, Inc.(Gentis) is a pharmaceutical company. It is principally engaged in the development of minimally synthetic, invasive, biomaterials-based products to treat the early-stage degeneration of the spine and for musculoskeletal. It offers DiscCell, an injectable, in-situ setting, radio-opaque, and non-hydrogel polymer material that replaces the diseased nucleus pulposus of the spinal disc. DiscCell is a novel biomaterial designed to restore the normal biomechanical function of a degenerated intervertebral disc by augmenting or replacing the gel like tissue at its center, the nucleus pulposus. Gentis is headquartered at Wayne in Pennsylvania, the US.